Discovery of a novel 2-(1H-pyrazolo[3,4-b]pyridin-1-yl)thiazole derivative as an EP1 receptor antagonist and in vivo studies in a bone fracture model
Keywords: EP1 receptor; Prostaglandin E2; Target validation; Oral administration; Bone fracture healing;